First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma

Current Oncology

View Publication Info
 
 
Field Value
 
Title First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma
 
Creator Bhella, S.
Varela, N.P.
Aw, A.
Bredeson, C.
Cheung, M.
Crump, M.
Fraser, G.
Kouroukis, T.
Sajkowski, S.
 
Subject Mantle cell lymphoma
first-line therapy
autologous stem cell transplantation
maintenance therapy
 
Description Background In Ontario, no clearly defined standard of care for the management of mantle cell lymphoma (mcl) has been developed, and substantial variability from centre to centre is evident. This guidance document was prompted by the need to harmonize practice in Ontario with respect to first-line, conditioning, and post transplantation maintenance therapy for patients newly diagnosed with transplantation-eligible mcl.
Methods The medline and embase databases were systematically searched from January 2013 to January 2020 for evidence, and the best available evidence was used to draft recommendations relevant to first-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of transplantation-eligible newly diagnosed mcl. Final approval of this guidance document was obtained from the Stem Cell Transplant Advisory Committee.
Recommendations These recommendations apply to all cases of transplantation-eligible newly diagnosed mcl:■ Alternating cycles of r-chop (rituximab plus cyclophosphamide–doxorubicin–vincristine–prednisolone) andr-dhap [rituximab plus dexamethasone–high-dose cytarabine–cisplatin] is the recommended first-line treatmentfor symptomatic patients newly diagnosed with mcl before autologous stem-cell transplantation (asct).■ Rituximab plus hyperfractionated cyclophosphamide–vincristine–doxorubicin–dexamethasone (r–hypercvad),alternating with methotrexate and cytarabine, is not recommended for the treatment of patients with newlydiagnosed mcl.■ beam (carmustine–etoposide–cytarabine–melphalan), beac (carmustine–etoposide–cytarabine–cyclophosphamide),and total-body irradiation–based regimens are reasonable conditioning options for patients with mcl whohave responded to first-line therapy and who are undergoing asct.■ Maintenance therapy with rituximab is recommended for patients with newly diagnosed mcl who have undergoneasct.
 
Publisher Multimed Inc.
 
Date 2020-07-29
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
application/pdf
text/html
 
Identifier http://www.current-oncology.com/index.php/oncology/article/view/7053
10.3747/co.27.7053
 
Source Current Oncology; Vol. 27 No. 6 (2020)
1718-7729
1198-0052
 
Language eng
 
Relation http://www.current-oncology.com/index.php/oncology/article/view/7053/9655
http://www.current-oncology.com/index.php/oncology/article/view/7053/9535
http://www.current-oncology.com/index.php/oncology/article/view/7053/9713
 
Rights Copyright (c) 2020 Multimed Inc.
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library